Bendamustin v terapii nekhodzhkinskikh limfom

Abstract



About the authors

A A Semenova

References

  1. United States Food and Drug Administration. Approval letter NDA 22-249. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/ 022249s000ltr.pdf
  2. United States Food and Drug Administration. Approval letter NDA 22-303. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/ 022303s000ltr.pdf
  3. Anger G, Hesse P, Baufield H. Treatment of multiple myeloma with a new cytostatic agent: g-1-methyl-5-bis-(b-chlorethyl)-amino-benzimidazolyl-(2)-butyric acid hydrochloride. Dtsch Med Wochenschr 1969; 94: 2495-500.
  4. Leoni LM, Bailey B, Reifert J et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008; 14: 309-17.

Statistics

Views

Abstract - 8

Cited-By


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies